JohnMMarisMD

Pediatric Hematology & Oncology • Philadelphia, PA

Professor, Pediatrics, Perelman School of Medicine

Join to view full profile

Dr. Maris is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Maris' full profile

Already have an account?

Office
34th & Civic Center Blvd
Children's Hospital Of Philadelphia
Philadelphia, PA 19104
Phone+1 215-590-1000

Fax+1 215-561-0959
Is this information wrong?

Education & Training

Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1992 - 1995
Children's Hospital of PhiladelphiaResidency, Pediatrics, 1989 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1989

Certifications & Licensure

NJ State Medical License 1993 - Present
PA State Medical License 1991 - 2024
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Philadelphia Magazine Castle Connolly, 2005-2006, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Elected Member The American Society for Clinical Investigation, 2007
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation Start of enrollment: 2004 Mar 01
Completed
Phase 1
N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma Start of enrollment: 2003 Aug 01
Completed
Phase 1
N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma Start of enrollment: 2005 Sep 01
Completed
Phase 2
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma Start of enrollment: 2005 Apr 01
Completed
Phase 2
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma Start of enrollment: 2005 Dec 01
Completed
Phase 1
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions Start of enrollment: 2006 Dec 11
Completed
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma Start of enrollment: 2006 Dec 01
Completed
Phase 1
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Available
Biomarkers in Young Patients With Neuroblastoma Start of enrollment: 2010 Jul 01
Completed
Next Generation Personalized Neuroblastoma Therapy Start of enrollment: 2016 Jul 01
Terminated
Phase 1
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Start of enrollment: 2016 Dec 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

The Virtual Child.
Richard J Gilbertson, Sam Behjati, Anna-Lisa Böttcher, Marianne E Bronner, Matthew Burridge, Henrick Clausing, Harry Clifford, Tracey Danaher, Laura K Donovan, Jarno D...> ;Cancer Discovery. 2024 Apr 4
ALK upregulates POSTN and WNT signaling to drive neuroblastoma.
Miller Huang, Wanqi Fang, Alvin Farrel, Linwei Li, Antonios Chronopoulos, Nicole Nasholm, Bo Cheng, Tina Zheng, Hiroyuki Yoda, Megumi J Barata, Tania Porras, Matthew L...> ;Cell Reports. 2024 Mar 26
3 citations
Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma.
Mooney, B., Negri, G., Shyp, T., Delaidelli, A., Zhang, H., Spencer Miko, S., Weiner, A., Radaoui, A., Shraim, R., Lizardo, M., Hughes, C., Li, A., El-Naggar, A., Roul...> ;Clinical Cancer Research. 2024 Mar 1
1 citations
Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion.
Yi Sun, Tyler J Florio, Sagar Gupta, Michael C Young, Quinlen F Marshall, Samuel E Garfinkle, Georgia F Papadaki, Hau V Truong, Emily Mycek, Peiyao Li, Alvin Farrel, N...> ;Science Immunology. 2023 Dec 1
3 citations
Targeting of intracellular oncoproteins with peptide-centric CARs.
Mark Yarmarkovich, Quinlen F Marshall, John M Warrington, Rasika Premaratne, Alvin Farrel, David Groff, Wei Li, Moreno di Marco, Erin Runbeck, Hau Truong, Jugmohit S T...> ;Nature. 2023 Nov 1
Retraction Note: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs.
Mark Yarmarkovich, Quinlen F Marshall, John M Warrington, Rasika Premaratne, Alvin Farrel, David Groff, Wei Li, Moreno di Marco, Erin Runbeck, Hau Truong, Jugmohit S T...> ;Nature. 2023 Nov 1
Integrative Genomic Analyses Identify LncRNA Regulatory Networks across Pediatric Leukemias and Solid Tumors.
Apexa Modi, Gonzalo Lopez, Karina L Conkrite, Chun Su, Tsz Ching Leung, Sathvik Ramanan, Elisabetta Manduchi, Matthew E Johnson, Daphne Cheung, Samantha Gadd, Jinghui ...> ;Cancer Research. 2023 Oct 13
1 citations
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.
Jung Kim, Zalman Vaksman, Laura E Egolf, Rebecca Kaufman, J Perry Evans, Karina L Conkrite, Arnavaz Danesh, Gonzalo Lopez, Michael P Randall, Maiah H Dent, Lance M Far...> ;Journal of the National Cancer Institute. 2024 Jan 10
BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.
Michael P Randall, Laura E Egolf, Zalman Vaksman, Minu Samanta, Matthew Tsang, David Groff, J Perry Evans, Jo Lynne Rokita, Mehdi Layeghifard, Adam Shlien, John M Mari...> ;Journal of the National Cancer Institute. 2024 Jan 10
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in-amplified neuroblastoma.
Hai-Feng Zhang, Alberto Delaidelli, Sumreen Javed, Busra Turgu, Taylor Morrison, Christopher S Hughes, Xiaqiu Yang, Manideep Pachva, Michael M Lizardo, Gurdeep Singh, ...> ;Science Advances. 2023 Aug 25
Polyclonal lymphoid expansion drives paraneoplastic autoimmunity in neuroblastoma.
Miriam I Rosenberg, Erez Greenstein, Martin Buchkovich, Ayelet Peres, Eric Santoni-Rugiu, Lei Yang, Martin Mikl, Zalman Vaksman, David L Gibbs, Dan Reshef, Amy Salovin...> ;Cell Reports. 2023 Aug 29
ROGUE: an R Shiny app for RNA sequencing analysis and biomarker discovery.
Alvin Farrel, Peng Li, Sharon Veenbergen, Khushbu Patel, John M Maris, Warren J Leonard> ;BMC Bioinformatics. 2023 Jul 29
2 citations
Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell state.
Nina Weichert-Leahey, Hui Shi, Ting Tao, Derek A Oldridge, Adam D Durbin, Brian J Abraham, Mark W Zimmerman, Shizhen Zhu, Andrew C Wood, Deepak Reyon, J Keith Joung, R...> ;The Journal of Clinical Investigation. 2023 May 15
5 citations
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Esther R Berko, Gabriela M Witek, Smita Matkar, Zaritza O Petrova, Megan A Wu, Courtney M Smith, Alex Daniels, Joshua Kalna, Annie Kennedy, Ivan Gostuski, Colleen Case...> ;Nature Communications. 2023 May 5
23 citations
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Kelly C Goldsmith, Julie R Park, Kimberly Kayser, Jemily Malvar, Yueh-Yun Chi, Susan G Groshen, Judith G Villablanca, Kateryna Krytska, Lillian M Lai, Patricia T Achar...> ;Nature Medicine. 2023 May 1
2 citations
germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.
Michael P Randall, Laura E Egolf, Zalman Vaksman, Minu Samanta, Matthew Tsang, David Groff, J Perry Evans, Jo Lynne Rokita, Mehdi Layeghifard, Adam Shlien, John M Mari...> ;Biorxiv. 2023 Feb 3
2 citations
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncolog...
Amy K Erbe, Mitch B Diccianni, Rajen Mody, Arlene Naranjo, Fan F Zhang, Jen Birstler, KyungMann Kim, Arika S Feils, Jung-Tung Hung, Wendy B London, Barry L Shulkin, Va...> ;Journal for Immunotherapy of Cancer. 2023 Feb 1
1 citations
Germline pathogenic variants in 786 neuroblastoma patients.
Jung Kim, Zalman Vaksman, Laura E Egolf, Rebecca Kaufman, J Perry Evans, Karina L Conkrite, Arnavaz Danesh, Gonzalo Lopez, Michael P Randall, Maiah H Dent, Lance M Far...> ;Medrxiv. 2023 Jan 25
Dr Audrey E. Evans (1925-2022): academic trailblazer par excellence.
Max J Coppes, John M Maris> ;Pediatric Research. 2023 Jun 1
6 citations
Genome wide DNA methylation analysis identifies novel molecular subgroups and predicts survival in neuroblastoma.
H Lalchungnunga, Wen Hao, John M Maris, Shahab Asgharzadeh, Kai-Oliver Henrich, Frank Westermann, Deborah A Tweddle, Edward C Schwalbe, Gordon Strathdee> ;British Journal of Cancer. 2022 Nov 1
12 citations
Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma.
Kristopher R Bosse, Anna Maria Giudice, Maria V Lane, Brendan McIntyre, Patrick M Schürch, Guillem Pascual-Pasto, Samantha N Buongervino, Sriyaa Suresh, Alana Fitzsimm...> ;Cancer Discovery. 2022 Dec 2
12 citations
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors.
Jessica B Foster, Crystal Griffin, Jo Lynne Rokita, Allison Stern, Cameron Brimley, Komal Rathi, Maria V Lane, Samantha N Buongervino, Tiffany Smith, Peter J Madsen, D...> ;Journal for Immunotherapy of Cancer. 2022 Sep 1
3 citations
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
Vandana Batra, Minu Samanta, Mehran Makvandi, David Groff, Paul Martorano, Jimmy Elias, Pietro Ranieri, Matthew Tsang, Catherine Hou, Yimei Li, Bruce Pawel, Daniel Mar...> ;Clinical Cancer Research. 2022 Sep 15
7 citations
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak, Arlene Naranjo, Wendy B London, Sheena C Tenney, Mitchell Diccianni, Jacquelyn A Hank, Marguerite T Parisi, Barry ...> ;Journal of Clinical Oncology. 2022 Dec 10
1 citations
Evaluation of the DLL3-targeting antibody-drug conjugate rovalpituzumab tesirine in preclinical models of neuroblastoma.
Kateryna Krytska, Colleen E Casey, Jennifer Pogoriler, Daniel Martinez, Komal S Rathi, Alvin Farrel, Esther R Berko, Matthew Tsang, Renata R Sano, Nathan Kendsersky, S...> ;Cancer Research Communications. 2022 Jul 1
Join now to see all

Press Mentions

Collaboration Aims to ‘Truly Accelerate Better Treatments’ for Pediatric CancersMay 9th, 2023
Perelman School of Medicine Awards & Accolades: December 2022January 24th, 2023
Gilbert Family Foundation Commits $23M to Vision Restoration and Brian Tumor InitiativesNovember 15th, 2022
Join now to see all

Grant Support

The Genetic Basis Of Neuroblastoma TumorigenesisNational Cancer Institute2008–2012
Cancer Center Research Training ProgramNational Cancer Institute2008–2011
Significance Of Genetic Alterations In NeuroblastomaNational Cancer Institute2004–2006
Isolation Of The Neuroblastoma Predisposition GeneNational Cancer Institute2004–2006
Chp677: I-MIBG Therapy For Refractory Neuroblastoma: Phase II StudyNational Center For Research Resources2004
Significance Of Genetic Alterations In NeuroblastomaNational Cancer Institute2002–2003
Isolation Of The Neuroblastoma Predisposition GeneNational Cancer Institute1998–2003
Isolation Of The Neuroblastoma Predisposition GeneNational Center For Research Resources2000–2002
Buthionine Suifoximine In Combination With Melphalan For Pediatric NeuroblastomaNational Center For Research Resources1998–2002
Significance Of Allelic Deletions In NeuroblastomaNational Cancer Institute1998–1999